Inventor · disambiguated record
Marije Overdijk
Also filed as: OVERDIJK MARIJE · OVERDIJK MARIJE BERBER
9 granted patents·14 pending applications·36 citations·filing 2012–2024
86Inventor score
Top patents by PatentIndex Score
23 records- 0195US11396553B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Jul 26, 2022·8 cites·23 claims
- 0294US11512137B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Nov 29, 2022·10 cites·10 claims
- 0394US11034772B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Jun 15, 2021·7 cites·20 claims
- 0490US10882913B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2019·Granted Jan 5, 2021·4 cites·23 claims
- 0580US9540433B2Human antibodies and antibody-drug conjugates against CD74VERPLOEGEN SANDRA·Filed 2012·Granted Jan 10, 2017·6 cites·43 claims
- 0680US2024117064A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 0777US12448459B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Oct 21, 2025·0 cites·23 claims
- 0876US2022411522A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 0975US12351650B2Antibodies binding to fibroblast activation protein alpha and death receptor 4GENMAB AS·Filed 2024·Granted Jul 8, 2025·0 cites·34 claims
- 1075US12173076B2Polypeptide variants and uses thereofGENMAB BV·Filed 2018·Granted Dec 24, 2024·1 cites·15 claims
- 1173US12247080B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2020·Granted Mar 11, 2025·0 cites·15 claims
- 1273US2025326854A1Polypeptide variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 1369US2022323582A1Human antibodies and antibody-drug conjugates against cd74GENMAB AS·Filed 2021·Application pending·0 cites
- 1466US2023107363A1Polypeptide variants and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1564US2020270359A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING BV·Filed 2018·Application pending·0 cites
- 1661US2019202926A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 1761US2019144554A1Anti-dr5 antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 1859US2023399414A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 1953US2023293680A1A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myelomaGENMAB BV·Filed 2021·Application pending·0 cites
- 2049US2017173151A1Human antibodies and antibody-drug conjugates against cd74GENMAB AS·Filed 2016·Application pending·0 cites
- 2148US2022315661A1Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancerGENMAB BV·Filed 2020·Application pending·0 cites
- 2247US2019276549A1Polypeptide variants and uses thereofGENMAB BV·Filed 2017·Application pending·0 cites
- 2346US2024252635A1Pharmaceutical compositions comprising bispecific anti-cd37 antibodiesGENMAB HOLDING B V·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marije Overdijk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →